Denne oppgaven tar for seg renal denervering og ser på hvilken plass renal denervering har i den kliniske praksis.Det er tidligere skrevet om dette, og det legges derfor vekt på utviklingen som har funnet sted det siste året, med særlig vekt på den siste av Symplicity HTN-studiene og norske studier. Etter gjennomgang av randomiserte, blindede og til dels sham-kontrollerte studier, later det til at RDN ikke rutinemessig bør inngå i behandlingen av pasienter med TH.
Both globally and in Norway, hypertension is a major contributor to the total burden of disease. When it comes to cardiovascular diseases like coronary artery disease, ischemic and hemorrhagic stroke and peripheral vascular disease, as well as renal failure, hypertension greatly increases the risk of being plagued by disease. Although a significant number of people suffering from hypertension are untreated, antihypertensive treatment is a matter of the utmost importance. Among patients receiving antihypertensive treatment, there are patients not achieving treatment goal and are said to be suffering from treatment resistant hypertension. Renal denervation has been announced as a new option of treatment for these patients. The first study on renal denervation was published in 2009 and led to a wave of optimism and enthusiasm. When prospective, randomised, controlled and blinded studies have been performed, the results concerning the blood pressure-lowering effects of renal denervation have changed from promising to be indicating doubtful effect. More than 20 000 patients have had performed renal denervation on their nerves, based on almost no evidence at all. Adjusted drug treatment seems to be superior to renal denervation in treatment of hypertension, and renal denervation should no longer be a part of the routine treatment of hypertension.